Plasmid

Yapan Bio Adds New Process Development Facility; Expands Capacity and Capabilities in Large Molecule Therapeutics

Retrieved on: 
Tuesday, October 18, 2022
API, Allergan, Commerce, Founder, Growth, Ministry of Industry, Commerce and Supplies (Nepal), The Carlyle Group, Ophthalmology, Vaccine, GMP, CGMP, Patient, Contract, Human, RNA, PPL, Plasmid, Partnership, McNeil Consumer Healthcare, PPS, Industry, E&C, CDMO, IAS, Information technology, Principal, Clinical trial, DNA, PCC, Solution, Strategic business unit, Fine chemical, Piramal, Genome Valley, Alvin Yapan

The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.

Key Points: 
  • The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.
  • Rama Rao stated,"It is heartening to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley.
  • It's evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients.
  • In 2021, Piramal Pharma Solutions made an equity investment in Yapan Bio, enabling Yapan to take the business through its next phase of growth.

Yapan Bio Adds New Process Development Facility; Expands Capacity and Capabilities in Large Molecule Therapeutics

Retrieved on: 
Tuesday, October 18, 2022
API, Allergan, Commerce, Founder, Growth, Ministry of Industry, Commerce and Supplies (Nepal), The Carlyle Group, Ophthalmology, Vaccine, GMP, CGMP, Patient, Contract, Human, RNA, PPL, Plasmid, Partnership, McNeil Consumer Healthcare, PPS, Industry, E&C, CDMO, IAS, Information technology, Principal, Clinical trial, DNA, PCC, Solution, Strategic business unit, Fine chemical, Genome Valley, Alvin Yapan

MUMBAI, India, Oct. 18, 2022 /PRNewswire/ -- Piramal Pharma Limited (PPL) today announced that Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India.

Key Points: 
  • The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure.
  • Rama Rao stated,"It is heartening to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley.
  • It's evidence of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients.
  • In 2021, Piramal Pharma Solutions made an equity investment in Yapan Bio, enabling Yapan to take the business through its next phase of growth.

AGC Biologics Honored for Innovations in Cell Line Development

Retrieved on: 
Thursday, October 13, 2022
AI Global Media, Plasmid, RNA transfection, Immortalised cell line, PD, Specialization, Escherichia coli, Contract, Research, RNA, Degenerative disease, CO, CDMO, Mab, CLD, GLOBE, DNA, AGC, Fine chemical

AGC Biologics has a Cell Line Development program backed by several decades of scientific expertise and research.

Key Points: 
  • AGC Biologics has a Cell Line Development program backed by several decades of scientific expertise and research.
  • Further, AGC Biologics in-house quality and regulatory teams ensure cell line development projects are ready for any stage, across any regulatory market, anywhere in the world.
  • AGC Biologics also invests in the latest research and development needs for its Cell Line Development program, including evaluating CHO-K1 GS knockout cell lines and transposase technology for increased DNA integration and high-producing cell lines, to diversify its portfolio.
  • AGC Biologics currently has four locations offering cell line development services, Seattle, WA and Boulder, CO , USA, Copenhagen, Denmark , and Chiba, Japan .

Ray Therapeutics and Forge Biologics Expand Their Viral Vector cGMP Partnership to Encompass Plasmid DNA Manufacturing

Retrieved on: 
Monday, October 10, 2022
Other Manufacturing, Research, Genetics, Clinical Trials, Manufacturing, Biotechnology, Health, Pharmaceutical, Science, Ignition, CA, Retina, Therapy, Retinal ganglion cell, Prevalence, Optogenetics, Retinal degeneration, Field line, Light, CGMP, Person, Biotechnology, Patient, B cell, Research, Program, Multimedia, Â, Severe cognitive impairment, Plasmid, Partnership, Retinitis, Visual acuity, Nyctalopia, Neuron, Ray, AAV, RP, CEO, RGC, DNA, Central retinal artery occlusion, HEK, Retinitis pigmentosa, Pharmaceutical industry, Vaccine, Hearth, Forge

View the full release here: https://www.businesswire.com/news/home/20221010005240/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221010005240/en/
    Forge will provide research-grade and GMP-Pathway plasmid manufacturing services, in addition to adeno-associated viral vector (AAV) process development, scale-up engineering, and cGMP manufacturing services for Ray Therapeutics program, RTx-015.
  • The program will continue to utilize Forges platform manufacturing processes, including its proprietary HEK 293 suspension Ignition Cells and pEMBR adenovirus helper plasmid.
  • All development and cGMP manufacturing activities will occur at the Hearth, Forges 200,000 square foot gene therapy cGMP production facility in Columbus, Ohio.
  • Ray Therapeutics lead candidate RTx-015 uses intravitreal administration, from which the vector diffuses into the retina and transduces primarily the RGCs.

PharmaJet to Present Latest Research Showing Superior Immunogenicity with Their Needle-free Systems at Five Conferences in October

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Pharmaceutical, Medical Supplies, Health, Medical Devices, Infectious Diseases, Clinical Trials, Other Health, Adult, Therapy, Volunteering, Injection, COVID-19, Protamine, RNA transfection, Plasmid, Needle, ID, N/S, Electroporation, Vaccination, Review, Tropy, Cadila Healthcare, Use, Vaccine

Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.

Key Points: 
  • Intradermal Needle-free delivered vaccines can induce strong immune response comparable to intramuscular and subcutaneous injection with a fraction of the dose.
  • The presentations may also include data from collaborations including those with:
    1.
  • 3 The low dose Tropis group produced significantly increased B and T cell responses compared to a higher dose IM N/S vaccination.
  • Refer to Instructions for Use to ensure safe injections and to review risks.

Forge Biologics Fuels Gene Therapy Manufacturing Engine with Launch of Plasmid DNA Manufacturing Services to Support AAV Clients

Retrieved on: 
Tuesday, September 27, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, OH, AAV, Exhibition, CGMP, Bioreactor, Plasmid, Company, Patient, Research, DNA, Conference, GMP, Vaccine, Pharmaceutical industry, Hearth, Forge

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forges existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.

Key Points: 
  • Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced the new availability of plasmid DNA manufacturing to its suite of scalable manufacturing services for gene therapy programs, complementing Forges existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
  • Forges plasmid production services utilize single-use systems that seamlessly integrate into the Companys platform AAV manufacturing process, allowing continuity of manufacturing for clients and streamlined vendor management.
  • All plasmid production will occur at Forges manufacturing facility, the Hearth, in Columbus, OH, and is available exclusively to clients performing their AAV manufacturing at Forge.
  • The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing.

Helena Strigård appointed as new CEO of rapidly expanding NorthX Biologics

Retrieved on: 
Tuesday, September 20, 2022
Income, Therapy, Time, Karolinska University Hospital, Vinnova, Partner, A-DNA, Ministry, Ministry of Finance and Economic Planning (Ghana), Plasmid, Company, Partnership, Industry, CEO, Protein, Vaccine, Board, DNA, GLOBE, GMP, ATMP, Management, Farm Workers Union of Central Sweden, Matfors

MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Board of NorthX Biologics ("NorthX") has appointed Helena Strigrd as the new CEO.

Key Points: 
  • MATFORS, Sweden, Sept. 20, 2022 (GLOBE NEWSWIRE) -- The Board of NorthX Biologics ("NorthX") has appointed Helena Strigrd as the new CEO.
  • With that foundation, the Company has now appointed a new CEO, Helena Strigrd to continue the Companys growth.
  • NorthX Biologics provides process development and manufacturing services with expertise in plasmids, proteins and other advanced biologics.
  • NorthX Biologics is headquartered in Matfors, Central Sweden, and the team has been manufacturing biologics to GMP standards since 1992.

AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate

Retrieved on: 
Wednesday, September 7, 2022
Escherichia coli, Partnership, Enzyme, Conditional sentence, Inclusion bodies, CEO, RNA, Cell, Program, Gene, Virus-like particle, Allergy, Vaccine, Protein, AGC, Skin, DNA, Process, CGMP, Antigen, CDMO, GLOBE, IBH, Therapy, Contract, Plasmid, Founder, Specialization, RNA transfection, Horse, Degenerative disease, Pharmaceutical industry, Filago (plant)

Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply cGMP support for the pivotal studies.

Key Points: 
  • Through this partnership, Evax advances its Antigen VLP Conjugate product into the clinical stage, and AGC Biologics will supply cGMP support for the pivotal studies.
  • AGC Biologics is providing services at its Heidelberg facility using microbial-based protein biologics systems.
  • For many equine diseases only limited therapeutic treatment options are available with sometimes poor efficacy, said Dr. Antonia Gabriel, CEO and Founder of Evax.
  • Further, AGC Biologics and the capabilities at its Heidelberg site are an ideal fit to help guide us through this important phase of the journey.

Lonza and Touchlight collaborate on end-to-end mRNA offering

Retrieved on: 
Tuesday, September 6, 2022
CEO, Technology, RNA, Gene, Vaccine, Infection, TouchLight, API, DNA, GMP, CDMO, CHF, Biotechnology, Therapy, Plasmid, RNA transfection, CORE, Fine chemical

Access to this technology expands the options for Lonzas customers beyond the traditional method of working with plasmid DNA (pDNA), while continuing to benefit from the companys integrated mRNA manufacturing offering.

Key Points: 
  • Access to this technology expands the options for Lonzas customers beyond the traditional method of working with plasmid DNA (pDNA), while continuing to benefit from the companys integrated mRNA manufacturing offering.
  • Andr Goerke, Vice President, Business Unit Head mRNA, Lonza, commented: The strategic collaboration with Touchlight enables Lonza to further enhance its position as a global leader in mRNA manufacturing.
  • Karen Fallen, CEO, Touchlight DNA Services, added: We are delighted to provide Touchlight customers the benefits of an end-to-end mRNA offering through our collaboration with Lonza.
  • Lonza is the leading CDMO in mRNA manufacturing and has an established, global mRNA manufacturing network.

Biopharmaceutical Contract Manufacturing Markets: Growing Uptake of Branded Biologics and Biosimilars - Global Outlook & Forecast 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Biotechnology, Manufacturing, Other Manufacturing, Health, Pharmaceutical, AbbVie, CMOS, Technology, RNA, SME, Research, Samsung Biologics, Time, Vaccine, R, Samsung, GT, DNA, Union, Serum Institute of India, Investment, Catalent, CDMO, GMP, Medicine, Emergent, Diosynth, FDA, Wuxi, Plasmid, Merck Group, Boehringer Ingelheim, COVID-19, RNA transfection, Therapure BioPharma Inc, Acquisition, Growth, Marketing, Efficiency, CMO, Fine chemical, Generic drug, Retail, Gene

The "Biopharmaceutical Contract Manufacturing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biopharmaceutical Contract Manufacturing Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global biopharmaceutical contract manufacturing market is highly competitive, with a large pool of global, regional, and local vendors involved in the contract manufacturing of various biopharmaceuticals.
  • These companies hold a significant share in the global market and focus on continuous expansion in biopharmaceutical contract manufacturing, further intensifying the competition in the worldwide market.
  • Samsung Biologics is one of the active contract manufacturers that invested a considerable amount in enhancing their manufacturing capacity by volume.